Discovery and Preclinical Pharmacology of NX-2127, an Orally Bioavailable Degrader of Bruton’s Tyrosine Kinase with Immunomodulatory Activity for the Treatment of Patients with B Cell Malignancies-Reference-Cited by-同舟云学术

Discovery and Preclinical Pharmacology of NX-2127, an Orally Bioavailable Degrader of Bruton’s Tyrosine Kinase with Immunomodulatory Activity for the Treatment of Patients with B Cell Malignancies

Published:2024-02-01 Issue:4 Volume:67 Page:2321-2336
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Robbins Daniel W.¹,Noviski Mark A.¹,Tan Ying Siow¹,Konst Zef A.¹,Kelly Aileen¹,Auger Paul¹,Brathaban Nivetha¹,Cass Robert¹,Chan Ming Liang¹,Cherala Ganesh¹,Clifton Matthew C.¹,Gajewski Stefan¹,Ingallinera Timothy G.¹^ORCID,Karr Dane¹,Kato Daisuke¹,Ma Jun¹,McKinnell Jenny¹,McIntosh Joel¹,Mihalic Jeff¹,Murphy Brent¹,Panga Jaipal Reddy¹^ORCID,Peng Ge¹,Powers Janine¹,Perez Luz¹,Rountree Ryan¹,Tenn-McClellan Austin¹,Sands Arthur T.¹,Weiss Dahlia R.¹,Wu Jeffrey¹,Ye Jordan¹,Guiducci Cristiana¹,Hansen Gwenn¹,Cohen Frederick¹^ORCID

Affiliation:

1. Nurix Therapeutics, Inc., 1700 Owens St., San Francisco, California 94158, United States

Funder

Nurix Therapeutics

Publisher

American Chemical Society (ACS)

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.3c01007

Reference50 articles.

1. Biology and novel treatment options for XLA, the most common monogenetic immunodeficiency in man

2. The B-cell receptor signaling pathway as a therapeutic target in CLL

3. Role of Bruton’s tyrosine kinase in B cells and malignancies